Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
32
PCLOF Quote, Financials, Valuation and Earnings
Last price:
$0.02
Seasonality move
:
-5.4%
Day range:
$0.02 - $0.03
52-week range:
$0.02 - $0.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.17x
P/B ratio:
--
Volume:
14.2K
Avg. volume:
6.3K
1-year change:
-68.38%
Market cap:
$5M
Revenue:
$2.3M
EPS (TTM):
-$0.03
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, PharmaCielo Ltd. has -- downside to fair value with a price target of -- per share.
PCLOF vs. S&P 500
-
Over the past 5 trading days, PharmaCielo Ltd. has overperformed the S&P 500 by 14.16% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PharmaCielo Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PharmaCielo Ltd. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter PharmaCielo Ltd. reported revenues of $645.5K.
Earnings Growth
-
PharmaCielo Ltd. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter PharmaCielo Ltd. reported earnings per share of -$0.01.
Enterprise value:
17.6M
EV / Invested capital:
--
Price / LTM sales:
2.17x
EV / EBIT:
--
EV / Revenue:
7.88x
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
-13.19x
Price / Operating cash flow:
6.73x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$221.4K
Return On Assets:
-44.23%
Net Income Margin (TTM):
-264.45%
Return On Equity:
-1331.05%
Return On Invested Capital:
-62%
Operating Margin:
-50.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.1M | $1.9M | $2.2M | $974.3K | $645.5K | |
| Gross Profit | -$606.9K | -$1.5M | $221.4K | $285.1K | -$272.5K | |
| Operating Income | -$6.7M | -$5.7M | -$3.6M | -$618.7K | -$1.8M | |
| EBITDA | -$6.1M | -$4.1M | -$2.8M | -$435.6K | -$1.7M | |
| Diluted EPS | -$0.06 | -$0.06 | -$0.03 | -$0.01 | -$0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.2M | $2.9M | $2.7M | $2.6M | $2.5M | |
| Total Assets | $29.4M | $19.7M | $19.7M | $14.6M | $6.2M | |
| Current Liabilities | $7.9M | $5.3M | $6.1M | $16.9M | $16.9M | |
| Total Liabilities | $11.3M | $13.1M | $17.6M | $20.2M | $16.9M | |
| Total Equity | $18.1M | $6.7M | $2.1M | -$5.6M | -$10.7M | |
| Total Debt | $3.2M | $8.5M | $12.4M | $15.5M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.8M | -$2.4M | -$1.3M | -$405K | -$2.6M | |
| Cash From Investing | $151.5K | $193.9K | $5.4M | -- | $5.4M | |
| Cash From Financing | $3.4M | $2.2M | -$3.9M | $395.1K | -$2.7M | |
| Free Cash Flow | -$3.8M | -$2.4M | -- | -$405K | -- | |
PCLOF
Sector
Market Cap
$5M
$28.5M
Price % of 52-Week High
24.27%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.33%
1-Year Price Total Return
-68.38%
-21.18%
Beta (5-Year)
1.074
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.03
200-day SMA
Sell
Level
$0.04
Bollinger Bands (100)
Sell
Level
0.02 - 0.04
Chaikin Money Flow
Sell
Level
-114.7K
20-day SMA
Sell
Level
$0.03
Relative Strength Index (RSI14)
Buy
Level
50.02
ADX Line
Buy
Level
30.49
Williams %R
Neutral
Level
-56
50-day SMA
Sell
Level
$0.03
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Sell
Level
-35.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-17.6816)
Sell
CA Score
(Annual)
Level (-4.7199)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (12.1082)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PharmaCielo Ltd. operates as a pharmaceutical company. It engages in the processing and supplying all natural, medicinal-grade cannabis oil extracts, and related products to large channel distributors. The company was founded on July 14, 2014 and is headquartered in Toronto, Canada.
Stock Forecast FAQ
In the current month, PCLOF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PCLOF average analyst price target in the past 3 months is --.
-
Where Will PharmaCielo Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that PharmaCielo Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About PharmaCielo Ltd.?
Analysts are divided on their view about PharmaCielo Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PharmaCielo Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is PharmaCielo Ltd.'s Price Target?
The price target for PharmaCielo Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PCLOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PharmaCielo Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PCLOF?
You can purchase shares of PharmaCielo Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PharmaCielo Ltd. shares.
-
What Is The PharmaCielo Ltd. Share Price Today?
PharmaCielo Ltd. was last trading at $0.02 per share. This represents the most recent stock quote for PharmaCielo Ltd.. Yesterday, PharmaCielo Ltd. closed at $0.03 per share.
-
How To Buy PharmaCielo Ltd. Stock Online?
In order to purchase PharmaCielo Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PCLOF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PCLOF
Sector
P/E ratio
--
23.66x
PEG ratio
-0.06x
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
2.17x
1.61x
Growth Metrics
PCLOF
Sector
Revenue growth
-33.75%
4.8%
Earnings growth
52.63%
11.11%
Revenue (5-year growth)
2.89%
6.45%
Earnings forecast
--
-$0.20
Profitability
PCLOF
Sector
Profitability FY 2024
$341.5K
$3.6M
Return on invested capital
-62%
-31.15%
Return on assets
-44.23%
-27.72%
Return on equity
-1331.05%
-36.72%
Earnings Date
Last Earnings Date
Apr
29
Next Earnings Date
Dec
9
Estimated Next Earnings Date
Mar
10
Balance Sheet
PCLOF
Sector
Total cash
$184.4K
$27M
Short term investments
--
$25.7M
Total assets
$12.9M
$79.7M
Long term debt
$14.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is down 2.82% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 1.78% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is down 8.32% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
